Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

JNJ picks a PPAR

July 3, 2006 7:00 AM UTC

It would seem that the edema and weight gain associated with the two peroxisome proliferation activated receptor gamma agonists that are marketed for diabetes have left the door wide open for improved versions of these billion-dollar drugs. Yet the last several months have seen pharma companies shelve more than one late-stage next-generation PPAR modulator.

Last week, Johnson & Johnson placed a bet on a Phase II/III PPAR gamma modulator from Metabolex Inc. that has shown a similar ability to lower glucose, so far without the problematic side effects of the marketed drugs...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article